Filing summary
Issuer and period: The supplied filing is Graybug Vision, Inc.’s Form 10-K for the fiscal year ended December 31, 2022, filed March 8, 2023. This does not match the request metadata, which identifies CalciMedica, Inc.; the filing describes a proposed merger with CalciMedica.
Business context and reporting period
Graybug was a clinical-stage biopharmaceutical company with no approved products or product revenue. Following a strategic review, it terminated development of GB-102 and GB-401 in August 2022, reduced its workforce by 71%, and substantially curtailed operations. At year-end, its remaining programs were GB-501, in preclinical development, and GB-701, in drug discovery.
Graybug had agreed to an all-stock merger with CalciMedica. The filing anticipated a first-quarter 2023 closing, subject to conditions including Graybug stockholder approval. If completed, the combined company was expected to operate under CalciMedica’s business plan.
Financial results and liquidity
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | No product revenue reported | No product revenue reported |
| Research and development expense | $14.1 million | $18.9 million |
| General and administrative expense | $19.1 million | $17.0 million |
| Restructuring, impairment and terminated-program costs | $3.0 million | None reported |
| Total operating expenses | $36.2 million | $35.9 million |
| Net loss | $35.6 million | $35.8 million |
| Net loss per share, basic and diluted | $1.66 | $1.69 |
| Net cash used in operating activities | $22.9 million | $31.5 million |
At December 31, 2022, cash and cash equivalents were $17.3 million and short-term investments were $21.8 million, totaling $39.1 million. Current assets were $39.7 million and current liabilities $3.7 million. Total liabilities were $3.7 million; the filing reports no debt balance. Stockholders’ equity was $36.0 million and accumulated deficit was $204.8 million. No meaningful operating margin is available because the company reported no revenue.
Cash provided by investing activities was $27.0 million, primarily reflecting investment maturities and purchases; financing activities used $0.1 million. Management stated that year-end cash, cash equivalents and short-term investments were expected to fund operations for at least 12 months from the report’s issuance, based on a reduced operating plan and assuming the merger did not close. This is not an unconditional assurance of funding.
Material changes versus prior year
- Research and development expense fell 25%, mainly as the GB-102 Phase 2b extension ended in 2021 and staffing and activity were reduced; the 2022 total included $2.2 million of acquired in-process research and development from RainBio.
- General and administrative expense increased 12%, primarily due to strategic-review, merger, legal, accounting and investment-banking costs and higher stock-based compensation.
- Operating cash use declined from $31.5 million to $22.9 million. Net loss was broadly similar year over year.
- The company recorded $3.0 million of restructuring and impairment costs, including $1.6 million of asset impairment and $1.1 million of severance and termination benefits.
- Assets declined to $39.7 million from $69.1 million, largely alongside the reduction in short-term investments and disposal of property and equipment.
Outlook, risks and unusual items
- Merger and liquidity conditions: The merger agreement required at least $18 million of Graybug net cash at closing, subject to specified adjustments. Failure to meet conditions could terminate the transaction. Merger failure could prompt another strategic transaction, asset divestiture, further cost reductions, or liquidation.
- Transaction costs and obligations: Approximately $9.1 million of merger-related commitments were disclosed as due within three to six months, including estimated $5.5 million in change-in-control severance payments and accelerated equity awards; a further approximately $2.3 million investment-banking payment was contingent on closing. The filing also disclosed possible termination fees and expense reimbursements if the merger did not proceed.
- Subsequent CalciMedica loans: In February 2023, Graybug agreed to lend CalciMedica up to $2.0 million at 7.5% simple annual interest. Graybug had purchased $1.0 million of notes by February 24, 2023; the remaining amount was subject to conditions. These unsecured notes were included in the merger net-cash calculation under an amendment.
- Development risk: GB-501 had not been tested in humans; management’s stated goal was GMP material suitable for potential trials in 2024. GB-701 was still in discovery, with no candidate expected to be ready for preclinical development before after 2023. Both programs depended on financing, partners, third-party manufacturing and regulatory progress.
- Other risks: The filing highlights merger execution and dilution, potential liquidation, Nasdaq minimum-bid compliance, clinical and gene-therapy uncertainty, limited access to capital, third-party manufacturing reliance, intellectual-property and reimbursement risks, and cybersecurity risks in a fully remote workforce.
- Litigation: Four stockholder lawsuits and nine demand letters challenged disclosures in the merger proxy statement. Graybug said it believed the claims were without merit; outcomes remained uncertain. The company filed supplemental proxy disclosures on March 3, 2023.
- Financial reporting: The independent auditor gave an unmodified opinion on the financial statements. Management reported effective disclosure controls and internal control over financial reporting; the auditor did not attest to internal controls because of the company’s emerging-growth-company exemption.
Most important facts for investors to verify
- Confirm the intended issuer: this filing is Graybug Vision’s 2022 10-K, not a CalciMedica 10-K.
- Check subsequent filings for whether the merger closed, final net cash and ownership split, and the combined company’s operating plan and financing.
- Reconcile cash and short-term investments with merger-related payments, severance, transaction costs and the $18 million net-cash closing condition.
- Review the terms, repayment status and collectability of Graybug’s CalciMedica notes, including any additional borrowing.
- Verify the status and funding of GB-501 and GB-701, and whether the stated development timelines remain achievable.
- Follow the stockholder litigation, Nasdaq listing compliance and any reverse-stock-split or other capital-raising actions.